FDA to speed up approvals of generic biologic medicines as Trump targets high drug costs
Update: 2025-10-30
Description
The FDA announces plans to expedite the development of generic versions of complex biological drugs, or biosimilars, to lower prescription drug prices. This move aims to cut the approval process time in half, making it faster and more affordable for drug makers to bring these alternatives to market. The FDA also simplifies rules for pharmacists to substitute biosimilars, potentially saving Americans billions annually and offering more affordable treatments sooner.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
